Whanin Pharm (016580) - Total Liabilities

Latest as of December 2025: ₩57.88 Billion KRW ≈ $39.23 Million USD

Based on the latest financial reports, Whanin Pharm (016580) has total liabilities worth ₩57.88 Billion KRW (≈ $39.23 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 016580 net assets growth trend to track the company's year-over-year net asset growth rate.

Whanin Pharm - Total Liabilities Trend (2009–2025)

This chart illustrates how Whanin Pharm's total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of Whanin Pharm to measure how efficiently the company converts operating cash flow to free cash.

Whanin Pharm Competitors by Total Liabilities

The table below lists competitors of Whanin Pharm ranked by their total liabilities.

Company	Country	Total Liabilities
Quoc Cuong Gia Lai JSC VN:QCG	Vietnam	₫4.00 Trillion
Dimerix Ltd AU:DXB	Australia	AU$77.80 Million
OBI Pharma TWO:4174	Taiwan	NT$696.13 Million
Anderson Industrial Corp TW:1528	Taiwan	NT$3.22 Billion
Sunflow Sustain TA:SNFL	Israel	ILA551.59 Million
M.I.TECH Co.Ltd KQ:179290	Korea	₩13.75 Billion
Velo3D, Inc. NASDAQ:VELO	USA	$63.74 Million
SinoMedia Holding Limited F:SJY	Germany	€107.21 Million

Liability Composition Analysis (2009–2025)

This chart breaks down Whanin Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Whanin Pharm stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	4.04	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.14	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.12	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Whanin Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Whanin Pharm (2009–2025)

The table below shows the annual total liabilities of Whanin Pharm from 2009 to 2025.

Year	Total Liabilities	Change
2025-12-31	₩57.88 Billion ≈ $39.23 Million	+18.85%
2024-12-31	₩48.70 Billion ≈ $33.01 Million	+13.22%
2023-12-31	₩43.02 Billion ≈ $29.15 Million	+21.36%
2022-12-31	₩35.45 Billion ≈ $24.02 Million	-1.44%
2021-12-31	₩35.96 Billion ≈ $24.37 Million	+9.12%
2020-12-31	₩32.96 Billion ≈ $22.33 Million	+8.33%
2019-12-31	₩30.42 Billion ≈ $20.62 Million	+8.26%
2018-12-31	₩28.10 Billion ≈ $19.04 Million	-11.50%
2017-12-31	₩31.75 Billion ≈ $21.52 Million	+36.22%
2016-12-31	₩23.31 Billion ≈ $15.80 Million	+23.35%
2012-12-31	₩18.90 Billion ≈ $12.81 Million	+16.26%
2011-12-31	₩16.25 Billion ≈ $11.02 Million	+54.67%
2009-12-31	₩10.51 Billion ≈ $7.12 Million	--

About Whanin Pharm

KO:016580 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$103.98 Million

₩153.43 Billion KRW

Market Cap Rank

#18989 Global

#883 in Korea

Share Price

₩10050.00

Change (1 day)

+0.60%

52-Week Range

₩9230.00 - ₩12060.00

All Time High

₩24391.10